Company Description Patrys Limited, based in Perth, Australia and listed on the Australian Securities Exchange (ASX: PAB), is a clinical-stage biotechnology company pursuing a dual-platform development strategy.

This company is a specialised therapeutics business focused on unlocking the latent value of known compounds through reformulation and repurposing. Rather than de novo drug discovery, the company's model depends on rigorous, systematic identification of assets where a differentiated formulation, novel indication, or new patient population can generate a compelling commercial and clinical return.

Role Description The Head of Pipeline Strategy & Opportunity Assessment is a full-time, on-site role based in the Greater Perth Area, responsible for shaping and optimizing Patrys’ development pipeline across deoxymab and CNS programs. This role leads portfolio strategy, assessing scientific, clinical, regulatory, and commercial opportunities to prioritize assets and indications that align with the company’s goals and risk profile. The Head of Pipeline Strategy & Opportunity Assessment is a senior, cross-functional role responsible for scanning the early-stage IP landscape and building a prioritised pipeline of reformulation and repurposing candidates.

This role sits at the intersection of science, strategy, and commercialisation — translating fragmented signals from the research and IP environment into a coherent, investment-ready asset pipeline.

The role oversees market and competitive intelligence, supports partnership evaluations, and prepares strategic recommendations and presentations for executive leadership and the Board.



The individual will also help refine long-term growth plans, ensuring that Patrys’ pipeline remains balanced, value-driven, and responsive to emerging data and market dynamics.

Qualifications

Essential

– Advanced degree (PhD, PharmD, MD, or equivalent) in a relevant scientific discipline — pharmaceutical sciences, pharmacology, medicinal chemistry, or clinical medicine preferred.

– Minimum 5–8 years' experience in drug development, business development, or asset evaluation within the pharmaceutical or biotech industry.

– Proven ability to synthesise complex scientific, commercial, and IP data into clear strategic recommendations.

– Demonstrated experience evaluating reformulation or repurposing assets,

– Robust understanding of the drug development process from pre-clinical through to regulatory submission.

– Experience preparing and presenting investment-grade asset profiles or business cases to senior stakeholders.

Desirable

– Demonstrated experience evaluating reformulation or repurposing assets, with a working knowledge of formulation science and pharmaceutical development.

– Track record of sourcing and evaluating licensing or acquisition opportunities.

– Experience within a specialty pharma, reformulation-focused, or 505(b)(2) drug development environment.

– Familiarity with patent landscape analysis and freedom-to-operate assessments.

– Existing network within academic tech transfer, IP licensing, or early-stage biotech ecosystems.

– Exposure to deal structuring, term sheet review, or licensing negotiation.

– Experience working in or alongside a lean/scale-up organisation.

📌 Head of Pipeline Strategy & Opportunity Assessment (Perth)
🏢 Patrys
📍 Perth